Subcutaneous continuous infusion of interferon alfa-2b and ribavirin in hepatitis C genotype 1 nonresponders

Trial Profile

Subcutaneous continuous infusion of interferon alfa-2b and ribavirin in hepatitis C genotype 1 nonresponders

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Dec 2011

At a glance

  • Drugs Interferon alpha-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacogenomic
  • Acronyms SCIN-C
  • Most Recent Events

    • 13 Dec 2011 Results published in Antiviral Therapy.
    • 10 Mar 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 10 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top